Journal Browser Advanced Search Help
Journal Browser Advanced search HELP
Clin Mol Hepatol. 2019 Mar;25(1):12-20. English. Review. https://doi.org/10.3350/cmh.2018.0067
Park JH , Kim JH .
Department of Pathology, Seoul Metropolitan Government-Seoul National Uiversity Boramae Medical Center, Seoul, Korea.
Department of Pathology, Seoul National University College of Medicine, Seoul, Korea. junghokim@snuh.org
Department of Pathology, Seoul National University Hospital, Seoul, Korea.
Abstract

The liver is one of the most common sites to which malignancies preferentially metastasize. Although a substantial number of liver malignancies are primary tumors, including hepatocellular carcinoma and intrahepatic cholangiocarcinoma, the metastasis of carcinomas to the liver is relatively common and frequently encountered in clinical settings. Representative carcinomas that frequently metastasize to the liver include colorectal carcinoma, breast carcinoma, neuroendocrine tumors, lung carcinoma, and gastric carcinoma. The diagnostic confirmation of suspected metastatic lesions in the liver is generally achieved through a histopathologic examination of biopsy tissues. Although morphology is the most important feature for a pathologic differential diagnosis of metastatic carcinomas, immunohistochemical studies facilitate the differentiation of metastatic carcinoma origins and subtypes. Useful immunohistochemical markers for the differential diagnosis of metastatic carcinomas in the liver include cytokeratins (CK7, CK19, and CK20), neuroendocrine markers (CD56, synaptophysin, and chromogranin A), and tissue-specific markers (CDX2, SATB2, TTF-1, GCDFP-15, mammaglobin, etc.). Here, we provide a brief review about the pathologic differential diagnosis of major metastatic carcinomas in the liver.

Copyright © 2019. Korean Association of Medical Journal Editors.